| REVIEW |
|
| Year : 2021 | Volume
: 1
| Issue : 4 | Page : 139-142 |
|
|
Managing patients with inflammatory bowel disease during the COVID-19 pandemic
Balakrishnan S Ramakrishna
Institute of Gastroenterology, Hepatobiliary Science and Transplantation, SRM Institutes for Medical Science, Chennai, Tamil Nadu, India
Correspondence Address:
Balakrishnan S Ramakrishna
Institute of Gastroenterology, Hepatobiliary Science and Transplantation, SRM Institutes for Medical Science, Vadapalani, Chennai - 600 026, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/ghep.ghep_40_21
|
|
|
The coronavirus disease 2019 pandemic has paralyzed the world now for 20 months. SARS-CoV-2 infection appears to result in a number of inflammatory, thrombogenic, and immune events in susceptible individuals. Patients with inflammatory bowel disease (IBD) are on chronic immunosuppressive medication. Furthermore, they have relapses of disease that requires intensification of their immunosuppressive treatment. Our understanding of the management of such patients during a viral pandemic has significantly improved due to the scientific exchanges that have taken place, through print publication and virtual sharing of experiences among IBD caregivers. This brief review provides an overview of the basic immunology of SARS-CoV-2 infection, how it impacts patients with IBD and current guidelines on managing therapy for IBD patients during a pandemic.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
